V|LF-Spiro3D technology will be a game changer both for clinical research and clinical practice with the possibility to improve a large patient population outcomes suffering from pulmonary diseases.
For clinical research, the technology will provide a disruptive device to regionally evaluate the respiratory mechanics with combined morphological and functional parameters.
It will produce predictive novel biomarkers, not accessible by any other means, and yield better understanding and improved characterization of chronic and progressive lung diseases. For clinical application, it will advance disease detection, diagnosis, and informed treatment decisions.
Personalized medicine including optimization of patient’s drug delivery and therapy will be performed as well as prediction and monitoring of disease progression, therapeutic effectiveness, patient’s outcomes based on their specific phenotype.
Long term and lasting impact
A more efficient 3D diagnostic tool for lung pathophysiology with numerous additionally-available contrasts;
A lower-cost and smaller footprint platform for radiologists and pulmonologists;
An easy-to-apply powerful imaging technique with facilitated access to patients, patient self-management;
A broader perspective with added-value in other organs and with easier intervention. A better management of respiratory diseases will reduce their huge burden on society in terms of disability and premature mortality, direct health service costs and drugs prescribed, and indirect costs in lost production.
V|LF-Spiro3D is expected to foster pulmonologists’ and patients’ empowerment and autonomy as seeing one’s breathing from the inside ease understanding, caring, and curing one’s lung function and dysfunction.
We assume that 3D spirometry will be highly sensitive to any lung pathology which affects normal patients’ breathing and therefore relevant for early diagnosis and staging of lung diseases. For the sake of patient healthcare and healthcare economy, we do not envision any true replacement of current routine spirometry at standard fields but at low and very-low fields to broaden the high overall potential value of 3D MR spirometry.